JAMES PATRINELY to Programmed Cell Death 1 Receptor
This is a "connection" page, showing publications JAMES PATRINELY has written about Programmed Cell Death 1 Receptor.
Connection Strength
2.384
-
Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. JAMA Oncol. 2021 05 01; 7(5):744-748.
Score: 0.695
-
Survivorship in immune therapy: Assessing toxicities, body composition?and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand. Eur J Cancer. 2020 08; 135:211-220.
Score: 0.655
-
Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma. Cancer. 2020 08 01; 126(15):3448-3455.
Score: 0.652
-
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncol. 2021 06; 22(6):836-847.
Score: 0.174
-
The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer. BioDrugs. 2020 Aug; 34(4):495-503.
Score: 0.165
-
Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. J Immunother Cancer. 2021 05; 9(5).
Score: 0.043